AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1 to 27. Canceled.

28. (new) A method of treating Parkinson disease, which comprises administering to a patient having Parkinson disease a therapeutically effective amount of a compound of the formula:



wherein Y is -C(O)-, $-CH_2$, $-CH_2C(O)$-or SO_2;

X is H;

Z is $(C_{0-4}$-alkyl)-$C(O)R^3$, C_{1-4}-alkyl, $(C_{O-4}$-alkyl)-OH, $(C_{1-4}$-alkyl)-$O(C_{1-4}$-alkyl), $(C_{1-4}$-alkyl)-$SO_2(C_{1-4}$-alkyl), $(C_{0-4}$-alkyl)-$SO(C_{1-4}$-alkyl), $(C_{0-4}$-alkyl)-NH_2, $(C_{0-4}$-alkyl)-$N(C_{1-8}$ alkyl$)_2$, $(C_{0-4}$-alkyl)-N(H)(OH), or $CH_2NSO_2(C_{1-4}$-alkyl);

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or $(C_{1-4}$-alkyl)cycloalkyl;

R^3 is NR^4 R^5, OH, or O-$(C_{1-8}$-alkyl);

R^4 is H;

R^5 is -OH, or $-OC(O)R^6$; and

R^6 is C_{1-8}-alkyl, amino-$(C_{1-8}$-alkyl), $(C_{1-8}$-alkyl)-$(C_{3-6}$-cycloalkyl), C_{3-6}-cycloalkyl, phenyl, benzyl, or aryl,

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

29. (new) A method of claim 28, which comprises administering a therapeutically effective amount of at least one second active ingredient.

30. (new) A method of claim 29, wherein the second active ingredient is a dopamine agonist, a monoamine oxidase inhibitor (MAO), a catechol-O-methyltransferase inhibitor (COMT), amantadine, an acetylcholinesterase inhibitor, an antiemetic, or an anti-inflammatory agent.

31. (new) The method of claim 28, wherein the stereoisomer of the compound is a R or S enantiomer.

32. (new) The method of claim 28, wherein the compound is (R)-N-(2-(3-(acetoxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-7-chloro-3-oxoisoindolin-4-yl)cyclopropanecarboxamide of the formula:



33. (new) The method of claim 28, wherein the compound is (R)-N-(2-(3-(acetoxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide of the formula:



34. (new) The method of claim 28, wherein the compound is (R)-N-(2-(3-(cyclopropanecarbonyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide of the formula:



35. (new) The method of claim 28, wherein the compound is (R)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-3-(isobutyryloxyamino)-3-oxopropyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide of the formula:



36. (new) The method of claim 28, wherein the compound is (R)-N-(2-(3-(3,3-dimethylbutanoyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisoindolin-4-yl)cyclopropanecarboxamide of the formula:



37. (new) The method of claim 28, wherein the compound is cyclopropanecarboxylic acid {2-[2-(2,2-dimethyl-propionyloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide of the formula:



38. (new) The method of claim 28, wherein the compound is administered orally.

39. (new) The method of claim 38, wherein the compound is administered in the form of a tablet or capsule.

40. (new) The method of claim 38, wherein the compound is administered in the amount of from about 10 mg to about 2,500 mg per day.

41. (new) The method of claim 40, wherein the compound is administered in the amount of from about 100 mg to about 1,200 mg per day.

42. (new) The method of claim 40, wherein the compound is administered in the amount of from about 100 mg to about 800 mg per day.